Sulodexide

舒洛地特

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSulodexide
Drug Alias Name硫酸氨基脱氧葡聚糖sulodexidesulodexidumsulodexidaGlucoronylglucosaminoglycan sulphate +[14] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionGlycosaminoglycan stimulants
TargetsGlycosaminoglycan
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeDiabetes Complications +[12] 
Global Approved IndicationsDiabetes ComplicationsThrombosisAtherosclerosis
Approved Indications in ChinaDiabetes ComplicationsThrombosisAtherosclerosis
Original Approved Country/TerritoryMainland China
Original Approved Date2003/08/15
Country/TerritoryCzechiaUnited StatesNetherlands +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAlfasigma Spa
China Registration ClassN/A

Develop Information

Active CompaniesValue Outcomes LtdAlfasigma SpaAlfa Wassermann Spa
Inactive CompaniesSt Joseph University, Beirut, LebanonAjou University School Of MedicineThe University Of Iowa +[5] 
Active IndicationsPost-Acute COVID-19 SyndromeDiabetes ComplicationsVenous Insufficiency +[6] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Renal Insufficiency, ChronicGlomerulonephritis, Membranoproliferative +[6] 

Other Information

ATC CodeB01AB11
Related LinksWikipediaDrugBank